Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by European Commission (EC)
MPS IIIB affects an estimated 500 to 1,000 individuals worldwide, 2 causing severe central nervous system (CNS) symptoms. Despite the dire need, there are currently no approved treatments available for this condition. JR-446, developed using JCR's proprietary J-Brain Cargo ® technology, has shown promising non-clinical results in addressing the CNS symptoms of this challenging disorder, and it is currently being studied in a Phase I/II trial that is being conducted in Japan (JR-446-101) under a collaboration agreement between the two companies.
In September 2023, MEDIPAL and JCR entered into a licensing agreement in which MEDIPAL will commercialize JR-446 for MPS IIIB outside of Japan. In addition, MEDIPAL will support JCR in the clinical development of JR-446 in Japan, including the distribution of investigational drugs, disease awareness, and clinical trial advancement. 3
With the ODD, JR-446 will be eligible for various incentives to encourage the development in the European Union (EU).
About Orphan Drug Designation in the European Union
The European Commission implements orphan designation drug for promoting new drug development for rare diseases in which the prevalence of the condition affects no more than five in 10,000 people in the European Union (EU). Designated drugs are granted market exclusivity for 10 years in the EU, as well as scientific guidance. Fee reductions are also available depending on the status of the sponsor and the type of service required.
About Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)
Mucopolysaccharidosis type IIIB, or Sanfilippo syndrome type B, is an autosomal recessive disease caused by pathogenic mutations in the NAGLU gene, encoding a lysosomal enzyme involved in the degradation of heparan sulfate. With the accumulation of heparan sulfate in the central nervous system in the brain, individuals with this condition present rapid neurological decline, including sleep disorders, loss of speech, and behavioral changes, which may significantly affect the quality of life of patients and their families.
About the J-Brain Cargo ® Platform Technology
JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology J- Brain Cargo ®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology is IZCARGO ® (INN: pabinafusp alfa) and was approved in Japan for the treatment of a lysosomal storage disorder.
About MEDIPAL HOLDINGS CORPORATION
MEDIPAL is a holding company which controls, administers and supports the operating activities of companies in which it holds shares in the Prescription Pharmaceutical Wholesale Business; the Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business; and the Animal Health Products and Food Processing Raw Materials Wholesale and Related Business, and conducts business development for the MEDIPAL Group. For more information, visit https://www.medipal.co.jp/english/.
About JCR Pharmaceuticals Co., Ltd.
JCR is a global specialty pharmaceuticals company dedicated to advancing treatments for rare and genetic diseases. With nearly 50 years of expertise in Japan, JCR is expanding to the US, Europe, and Latin America. JCR's innovative therapies address conditions like growth disorder, MPS II, Fabry disease, acute graft-versus-host disease, and renal anemia. JCR is also developing treatments for rare diseases like MPS I, MPS II, MPS IIIA and B, and more. For more information, visit https://jcrpharm.com/.
Cautionary Statement Regarding Forward-Looking Statements
This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as 'believe,' 'estimate,' 'anticipate,' 'intend,' 'plan,' 'will,' 'would,' 'target' and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions. This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.
References
Reference: Press release on the orphan drug designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDA (May 7, 2025).
Based on data from JCR's own investigations, referring to the Ministry of Health, Labour and Welfare's public research.
Reference: Press release on the licensing agreement for JR-446 between MEDIPAL and JCR (September 28, 2023).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
42 minutes ago
- Business Wire
Haig Partners Q2 2025 Haig Report ®: Dealer Profits Grow 20% Thanks to One Time Events; Buy-Sell Volume Declines but Values Remain Strong
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--The U.S. auto retail industry just closed one of its most profitable quarters in years — but the driving forces may surprise you. According to the newly released Q2 2025 Haig Report ® from Haig Partners, public dealer group profits per store jumped 20% year-over-year, fueled in part by two unique, short-term tailwinds: "...The fundamentals remain healthy, demand to buy dealerships is strong, and dealers have shown again and again that they can adapt to whatever the market throws at them.' Favorable comparisons to June 2024's CDK dealer management systems outage, which crippled many dealers' operations during Q2 last year. A pre-tariff buying surge after President Trump's April 2 'Liberation Day' announcement, pulling forward sales at strong margins. 'These unusual boosts have made Q2 look stronger than it may prove to be for the rest of the year,' said Alan Haig, President of Haig Partners. 'But the fundamentals remain healthy, demand to buy dealerships is strong, and dealers have shown again and again that they can adapt to whatever the market throws at them.' Additional highlights from the Q2 2025 Haig Report ®: Franchise Valuation Changes – Toyota, Kia, and Hyundai/Genesis saw multiple increases this quarter, reflecting strong demand and buyer appetite. Audi suffered a sharp valuation cut as prolonged sales declines and inventory imbalances eroded buyer interest. Blue Sky Values at Record Levels – Average dealership blue sky values remain about twice pre-COVID, a figure bolstered by steady multiples and strong earnings despite slower buy-sell volume. Market Momentum Shifts – Private buyers are showing broader appetite, while public groups are increasingly selective — favoring top-performing brands or strategic bolt-ons. Pipeline Strength – Haig Partners is advising on 67 dealership transactions signed or closed in 2025, 18% more than last year, outpacing the market's overall slowdown. Dealership Buy-Sell Market: Slower First Half, Set to Rebound? 192 U.S. rooftops changed hands in 1H 2025 — down 39.4% from last year's pace. Drivers of the slowdown: dealership buy-sell activity was still healthy in Q2, but more delayed closings experienced due to election-year uncertainty, tariff headlines, and a value gap between buyer and seller expectations. Outlook: A clearer political and economic landscape is expected to reignite activity in the second half, though volumes may be shifting back to a volume of 300-400 dealership sales per year compared to the 550-700 sales per year we experienced during the COVID era when valuations exploded. Economic & Operational Outlook Tariffs will have an impact in Q3. The OEMs have absorbed the cost of the tariffs so far, but we expect this will begin to change in Q3 as higher prices are subtly passed on to dealers and customers. Some brands will be hurt more than others, which could reshuffle dealership valuations. Interest rate cuts are increasingly likely later in 2025, which could boost more dealership buy-sell activity in the second half, not mention increased vehicle affordability for customers. EV mandates are gone, reducing risks for dealers in former CARB states. Now that dealers can sell the vehicles that consumers want to buy, dealers in CARB states can rest assured that their businesses will remain viable and valuable. The regulatory changes are likely to have an impact on everyone in auto retail. During an interview with Alan Haig, Senator Bernie Moreno stated, 'And I think right now, if I was in the car business today, I would be investing, I'd be buying, I'd be growing, because you take advantage of the fact that some people don't know how to manage change.' Haig Partners is seeing this spirit among the many dealership buyers it speaks with every week. Alan Haig said, 'Public and private buyers are trying to expand in this environment. Despite the unknown impact of tariffs, most of the larger groups are seeking to expand, and many smaller ones as well. And no one is calling us desperate to sell.' At Haig Partners, we are deeply grateful to the dealers, industry partners, and clients who place their trust in The Haig Report ® as a resource for navigating the dynamic automotive retail market. We recognize that selling a dealership is not only one of the most significant financial decisions in a dealer's career, but also one of the most personal. It is an honor to be invited into that process, to provide both the market insights that inform strategy and the expert guidance that helps our clients achieve the outcomes they deserve. Our team takes great pride in serving as a trusted advisor, combining decades of transaction experience with a deep respect for the legacy and future of each business we touch. We invite dealers considering a sale or acquisition to connect with us and explore how we can help maximize value and ensure a smooth, successful transition. About The Haig Report ® The Haig Report ®, the longest-published quarterly report tracking trends in auto retail and their impact on dealership values, includes data and analysis on the performance of auto dealerships, discusses noteworthy events impacting the automotive retail industry, identifies trends in the M&A market for dealerships, provides guidance on estimated value ranges for different franchises and shares an outlook for the automotive retail buy-sell market. The Haig Report ® is based on data gathered from reputable public sources and interviews with leading dealer groups and dealers, bankers, lawyers and accountants who specialize in auto retail. About Haig Partners Haig Partners is a leading buy-sell advisory firm that helps owners of higher-value dealerships maximize the value of their businesses when they are ready to sell. The team at Haig Partners has advised on the purchase or sale of more than 525 dealerships with a total value of over $10.6B. It has represented 30 dealership groups that qualify for the Top 150 Dealership Groups list published by Automotive News, more than any other firm. Clients of Haig Partners benefit from the group's collective experience as previous executives with leading companies such as Ally Financial, AutoNation, Bank of America, Credit Suisse, Deloitte, FORVIS, J.P. Morgan, the Sewell Automotive Companies and Toyota Financial Services. Leveraging its unmatched expertise and extensive relationships, Haig Partners guides clients to successful outcomes through a confidential and customized sales process. The firm authors The Haig Report ®, the leading industry quarterly report that tracks trends in auto retail and their impact on dealership values, and co-authors NADA's Guide, 'Buying and Selling a Dealership.' Haig Partners team members are frequent speakers at industry conferences and are regularly quoted in reputable media outlets, including Reuters, Forbes, The Wall Street Journal, The New York Times, CNBC, BBC, Automotive News, Wards, CarDealershipGuy and CBT News. For more information, visit
Yahoo
an hour ago
- Yahoo
Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in people living with obesity (SELECT study) Additional Rybelsus® and Ozempic® data demonstrate new cardiometabolic benefits (improvements in heart and metabolic health) in people living with type 2 diabetes (SOUL and STRIDE studies) New insights into the role of inflammation in cardiovascular disease on mortality and major cardiovascular events in people living with inflammation in the heart vessels Bagsværd, Denmark, 20 August 2025 – Novo Nordisk today announced new data showing the cardiovascular protective benefits of Wegovy® and Ozempic® will be presented at the European Society of Cardiology (ESC) Congress 2025 from 29 August to 1 September in Madrid, Spain. New data will also include perspectives on the role of inflammation in a condition called atherosclerotic cardiovascular disease (ASCVD). 'For people living with diabetes and obesity, heart disease is one of the biggest threats that could change a person's life in an instant. Semaglutide is proven to reduce the risk of cardiovascular events by 20-26%1, meaning fewer hospitalisations, heart attacks, stroke and deaths,' said Ludovic Helfgott, executive vice president and head of Product & Portfolio Strategy at Novo Nordisk. The key role of cardiovascular inflammation in ASCVD will be discussed in a Novo Nordisk symposium on Saturday, 30 August. ASCVD is a condition where blood vessels that carry blood to your heart cut off the blood flow to other parts of your body, making those vessels stiff and narrow. Additionally, a range of real-world evidence is being presented, providing a thorough analysis of the impact of inflammation in cardiovascular disease on mortality and major cardiovascular events in people with ASCVD. Real-world evidence is data from everyday healthcare settings that show how treatments work in real life, beyond controlled clinical trials. 'At the ESC congress, we are presenting new data substantiating the unique range of benefits semaglutide has on people with heart and kidney disease, as demonstrated in both clinical trials and in the real world,' Ludovic Helfgott said. 'Semaglutide is unrivalled in the GLP-1 class with its proven reduction in heart attack, stroke, kidney complications and cardiovascular death.' Key Novo Nordisk data at the ESC congress 2025 include: Scientific Sessions: Unravelling cardiovascular inflammation in atherosclerotic cardiovascular disease (ASCVD): from evidence to guidance – Saturday 30 August; 10:00 – 10:45 CEST GLP-1RAs in obesity-related HFpEF: a new era in treatment – Sunday 31 August; 10:00 –10:45 CEST A change of heart – why cardiologists can't ignore semaglutide – Sunday 31 August; 12:30 – 13:30 CEST Poster and oral presentations:Ozempic® (once-weekly semaglutide 1.0 mg) Effect of semaglutide in patients with type 2 diabetes and peripheral artery disease: an analysis of the STRIDE trial stratified by disease severity and age – Friday 29 August; 08:35 – 08:45 CEST STRIDE Outcomes by Sex – Sunday 31 August; 09:15 – 09:30 CEST Rybelsus® (once-daily oral semaglutide) Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial – Friday 29 August; 14:40 – 14:50 CEST Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis – Saturday 30 August; 08:33 – 08:51 CEST Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes – Monday 1 September; 13:15 – 14:00 CEST Wegovy® (once-weekly semaglutide 2.4 mg) Semaglutide effects on incidence and reoccurrence of atrial fibrillation in the SELECT trial – Friday 29 August; 14:30 – 14:40 CEST Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice – Sunday 31 August; 09:00 – 09:15 CEST Potential real-world benefit of semaglutide 2.4 mg on cardiovascular outcomes in the UK based on the SELECT trial – Sunday 31 August; 17:40 – 17:50 CEST Relationship between baseline LDL cholesterol levels and cardiovascular outcomes in adults with cardiovascular disease and overweight or obesity: an exploratory analysis of the SELECT trial – Monday 1 September; 13:15 – 14:00 CEST Cardiovascular inflammation Associations between C-reactive protein levels and mortality in individuals with atherosclerotic cardiovascular disease and chronic kidney disease: results from the UK Discover database – Friday 29 August; 08:51 – 09:09 CEST Residual inflammation, cholesterol risks and rates of major cardiovascular events in routinely cared patients with atherosclerotic cardiovascular disease – Sunday 31 August; 08:45 – 08:55 CEST Direct healthcare costs for individuals with atherosclerotic cardiovascular disease, chronic kidney disease stages 3–4 or both: results from the UK Discover database – Monday 1 September; 14:15 – 15:00 CEST Awareness and perceptions on the role of systemic inflammation in atherosclerotic cardiovascular disease and chronic kidney disease: a national study among cardiologists and nephrologists in China – Monday 1 September; 14:15 – 15:00 CEST General obesity Cardiovascular outcomes in a SELECT-like obesity population: real-world insights from the Swedish AROS study – Saturday 30 August; 10:15 – 11:00 CEST If you have any questions about the data or want more information, reach out to globalmedia@ About semaglutideSemaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that mimics the effects of the naturally occurring hormone GLP-1. It has been tested in several robust clinical development programmes and outcomes studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease and other related cardiometabolic diseases1-8. Semaglutide is marketed under the brand names Wegovy® (once-weekly semaglutide 2.4 mg injection), Ozempic® (once-weekly semaglutide 1.0 mg injection), and Rybelsus® (once-daily oral semaglutide 14 mg)6-8. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Christoffer Sho Togo Tullin+45 3079 1471cftu@ Alex Bruce +45 34 44 26 13axeu@ Frederik Taylor Pitter +1 609 613 0568fptr@ _______________________References1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834-1844.2. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391:109-121.3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232.4. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275-286.5. McGuire DK, Marx N, Mulvagh SL, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392:2001-2012.6. Ozempic® (once-weekly semaglutide): Summary of Product Characteristics. Available at: Last accessed: August 2025.7. Wegovy® (semaglutide injection 2.4 mg): Summary of Product Characteristics. Available at: Last accessed: August 2025.8. Rybelsus® (once-daily oral semaglutide): Summary of Product Characteristics. Available at: Last accessed: August 2025. Attachment PR250820-Curtain-Raiser-ESC-2025
Associated Press
2 hours ago
- Associated Press
ACES Q1 2025 Mortgage QC Industry Trends Report reveals early signs of loan quality risk amidst mounting market pressures
- Defect rate increases from historic low as underwriting pressures, shifting borrower profiles and market volatility test lenders' quality control processes - DENVER, Colo., Aug. 20, 2025 (SEND2PRESS NEWSWIRE) — ACES Quality Management® (ACES), the leading provider of enterprise quality management and control software for the financial services industry, today announced the release of its quarterly ACES Mortgage QC Industry Trends Report covering the first quarter (Q1) of 2025. The latest report analyzes post-closing quality control data derived from ACES Quality Management & Control® software. Notable findings from the Q1 2025 report include the following: 'The rise in critical defects this quarter underscores how market volatility and operational pressure can impact loan quality,' said Nick Volpe, executive vice president at ACES Quality Management. 'At the same time, we're seeing that lenders who invest in automation and proactive quality control are making measurable improvements, particularly in underwriting and compliance.' Findings for the Q1 ACES Mortgage QC Industry Trends Report are based on post-closing quality control data derived from the ACES Quality Management and Control® benchmarking system and incorporate data from prior quarters and/or calendar years, where applicable. All reviews and defect data evaluated for the report were based on loan audits selected by lenders for full file reviews. The Mortgage QC Industry Trends Reports are available for download, free of charge, at About ACES Quality Management ACES Quality Management is the leading provider of enterprise quality management and control software for the financial services industry. The nation's most prominent lenders, servicers and financial institutions rely on ACES Quality Management & Control® Software to improve audit throughput and quality while controlling costs, including: Unlike other quality control platforms, ACES Flexible Audit Technology® gives independent mortgage lenders and financial institutions the ability to easily manage and customize ACES to meet their business needs without having to rely on IT or other outside resources. Using a customer-centric approach, ACES clients get responsive support and access to our experts to maximize their investment. For more information, visit or call 1-800-858-1598. LOGO link for media: NEWS SOURCE: ACES Quality Management ### MEDIA ONLY CONTACT: (not for publication online or in print) Lindsey Neal Depth for ACES Quality Management (404) 549-9282 [email protected] ### Keywords: Reports and Studies, Mortgage QC Industry Trends Report, ACES Quality Management, enterprise quality management and control software for the financial services industry, DENVER, Colo. This press release was issued on behalf of the news source (ACES Quality Management) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P128618 APNF0325A To view the original version, visit: © 2025 Send2Press® Newswire, a press release distribution service, Calif., USA. RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
